NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
ProteoDesign announces new Investment led by Ysios Capital and rebrands as Splice Bio<
15 Sep 2020

ProteoDesign announces new Investment led by Ysios Capital and rebrands as Splice Bio

ProteoDesign rebrands as Splice Bio to develop novel gene therapies based on its proprietary intein technology.
15 Sep 2020

Galecto’s Oral Galectin-3 Inhibitor GB1211 Well Tolerated in Phase 1 Clinical Data Presented Recently at Several Scientific Conferences

Galecto, Inc. today announced it has received Orphan Drug Designation from both the U.S. Food and Drug Administration and the European Medicines Agency for GB0139 in the treatment of Idiopathic Pulmonary Fibrosis.
Aura Biosciences Announces Dosing of First Patient in Phase 2 Study Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma<
11 Sep 2020

Aura Biosciences Announces Dosing of First Patient in Phase 2 Study Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma

AU-011 Continues to Demonstrate a Favorable Safety Profile Along with Promising Tumor Control and Vision Preservation.
09 Sep 2020

Medlumics raises €14M in a Series E financing co-led by Asabys Partners, VI Partners and CDTI Innvierte, together with existing investors Andera Partners, Caixa Capital Risc and Innogest

Medlumics announces today the closing of a €14 million Series E financing, co-led by Asabys Partners, VI Partners and CDTI Innvierte, with the participation from historical investors Andera Partners, Caixa Capital Risc and Innogest Capital.
27 Aug 2020

Galecto, Inc. Receives U.S. and EU Orphan Drug Designations for GB0139 in Idiopathic Pulmonary Fibrosis

Galecto, Inc. today announced it has received Orphan Drug Designation from both the U.S. Food and Drug Administration and the European Medicines Agency for GB0139 in the treatment of Idiopathic Pulmonary Fibrosis (IPF).
20 Aug 2020

Sanifit Appoints Adam Levy as Chief Financial Officer

Sanifit today announced the appointment of Adam Levy as Chief Financial Officer, with immediate effect.
21 Jul 2020

CorWave Awarded €2.5M From the European Commission Through the EIC Accelerator Program

CorWave will receive a €2.5 million grant from the European Innovation Council (EIC) to develop its innovative Left Ventricular Assist Device (LVAD).
20 Jul 2020

Sanifit to start new clinical development program of SNF472 in End Stage Kidney Disease patients with Peripheral Artery Disease

Sanifit announces that it will start a new clinical development program to investigate the effect of SNF472 in End Stage Kidney Disease (ESKD) patients with Peripheral Artery Disease (PAD), a cardiovascular disease affecting peripheral arteries by reducing blood flow to the limbs.
VarmX raises €32 million in Series B financing to develop innovative reversal agent for the treatment and prevention of severe bleeding in patients on oral anticoagulants<
08 Jul 2020

VarmX raises €32 million in Series B financing to develop innovative reversal agent for the treatment and prevention of severe bleeding in patients on oral anticoagulants

Ysios Capital co-leads EUR 32 million Series B financing in VarmX.
07 Jul 2020

CVRx® Raises $50 Million in New Equity Financing

CVRx, Inc. announced today that it raised $50 million to close its latest round of equity financing.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка